(Tan Qixin, a reporter from the Peoples Daily Health Client) On November 6, Novo announced the first three quarters of 2024, and its total revenue in the first three quarters was 204.720 billion Dan Yin Kron (about 29.850 billion U.S. dollars) Among them, the revenue contributed by Smeglugin was very bright, with a total of 1412.13 billion Dan Ying Cori (about 20.590 billion US dollars) in the three quarters.As of press time, the performance of multinational pharmaceutical companies in the third quarter has basically been disclosed. What best -selling medicines in the financial report are expected to become the global "medicine king" this year?
Paborzumab (K drug): The annual sales of the annual sales may exceed 30 billion US dollars
Mercks financial report shows that in the first three quarters of 2024, the companys cumulative revenue was about 48.544 billion US dollars, an increase of 7%year -on -year.In terms of products, only PD-1 antibody Paborzab ("K medicine") contributed US $ 21.646 billion in the first three quarters, an increase of 18%year-on-year.21%, maintain a higher growth rate.As a result, Merhado predicts that the annual sales of the drug may exceed 30 billion US dollars.
The strong growth of the sales of K drugs is inseparable from the expansion of indications. Based on the 9 adaptive diseases that have been approved before, the recent K -drug for local advanced head and neck scales for the surgery periodThe KEYNOTE-689 study of cancer has also achieved positive results, which is expected to become the 10th early early indications approved by Keytruda.
Simei Gutu peptide: sales increased by more than 40%year -on -year to $ 20.5 billion
NuoheNords financial report shows that the main growth driving force of its performance in the first three quarters of this year comes from the strong growth of sales of Smegugu peptide.
Specifically, the Sammeglugin peptide injection Ozempic sold in the first three quarters of the first three quarters of Dan Ying Crown (US $ 12.611 billion), an increase of 32%year -on -year;Rybelsuss Rybelsus revenue was 16.384 billion Dan Ying Crown (US $ 2.389 billion), an increase of 28%year -on -year; WeGovy revenue for the dietary inception of Smegugu peptide at 38.34 billion Dan Ying Crown (US $ 5.590 billion), an increase of 76%year -on -year.In the first three quarters of the three products, a total of 1412.13 billion Dan Yinghe, which was US $ 20.590 billion, a year -on -year increase of more than 40%.If this growth can be maintained, Simei Gutu peptides will exceed $ 27 billion throughout the year.
Urpo Peptide: annual income or over 16 billion US dollars
The GLP-1/GIP dual excitement that was shot once was first approved for diabetes in the United States in May 2022 in May 2022. It was approved for weight loss in the United States on November 8, 2023.In May of this year, the Dalp Peptide Diabetes Indication was approved in China, and the July weight loss indication certificate was also approved.
The financial report data of Lilly showed that the overall operating income of Lilly in the first three quarters of 2024 was 31.5 billion US dollars, an increase of 27%year -on -year, and net profit was 6.18 billion US dollars.Among them, Lillys heavy product Terpubon peptide reached $ 11 billion in the first three quarters. Among them, the sales of Nutrpptosaccharin belogoshuo version of Moujaro were US $ 8.00.0 billion.The weight loss version of ZEPBOUND sales of US $ 3.018 billion, and the annual revenue of Nutrpptide products exceeded 16 billion US dollars.Lilly announced that it will continue to expand production.
Aileen: Global sales in the first three quarters
The financial report data disclosed by Pfizer shows the display.In the first three quarters of 2024, Pfizers total revenue was approximately US $ 45.864 billion, a year -on -year increase of 2%. Among them, the revenue in the third quarter was US $ 17.702 billion, a year -on -year increase of 32%.Pfizer said that based on the growth of performance since this year, its decision will increase the annual revenue guidance of $ 1.5 billion, which is expected to reach US $ 61 billion to 64 billion.
Specifically, Eliquis, the worlds best -selling drug list on the list last year, is still dazzling.The dollar increased by 7.7%year -on -year.Aleci is a new type of oral XA factor inhibitor jointly developed and developed by
Public information shows that the indication of Du Pulibukegina has covered special dermatitis, asthma, COPD, chronic sinusitis with nasal polyp disease, eosinophone and esophagitis andNodular prurosty rash.
